Navigation Links
Vortex Biosciences Presents Studies at AACR That Demonstrate Use of the VTX-1 System for Isolating and Analyzing Circulating Tumor Cells for Cancer Research
Date:3/30/2017

Vortex Biosciences, provider of circulating tumor cell (CTC) capture systems, will present four posters at the American Association for Cancer Research (AACR) Annual Meeting 2017 (April 1–5, Washington D.C.). Data presented at AACR demonstrate the ability of Vortex’s technology to rapidly collect highly enriched populations of CTCs, undamaged by labels or reagents, for colorectal cancer, non-small cell lung cancer (NSCLC) and breast cancer research.

CTCs, shed by tumors, offer direct access to the intact cancer biology of the patient. The fully automated, easy to use VTX-1 Liquid Biopsy System from Vortex represents the next step in CTC isolation. Inside the VTX-1 chip, unlabeled CTCs in whole blood are selectively trapped in microscale vortices while smaller, less deformable red and white blood cells pass through. Afterwards, CTCs can be released and collected into a variety of containers for downstream analysis. With excellent cell capture efficiency, high flexibility, a low cost per run and a simple, easy to use workflow, the VTX-1 empowers researchers to unleash the potential of CTCs.

“The VTX-1 represents the next step in CTC isolation,” explained Vortex CEO Gene Walther. “The simplicity and performance of the system enables cancer researchers to directly access the cancer biology of the patient, opening doors for a greater understanding of cancer.”

Studies at AACR

In a first study, Genomic profiling of Vortex-enriched CTCs using whole genome amplification and multiplex PCR based targeted next generation sequencing (poster #1724, to be presented 8 a.m.–12 p.m., Monday April 3rd), Vortex developed and characterized a simple and efficient NGS workflow for CTC samples collected by Vortex technology. This workflow was then validated for the mutation profiling of colorectal cancer patient CTCs. For each patient, variants in CTCs and germline WBCs were analyzed from one blood sample using an optimized targeted NGS workflow and compared to liver metastases.

A second study, Establishing the use of Vortex technology for investigating circulating tumor cells in mouse models of breast cancer. (poster #2822, to be presented 1 p.m.–5 p.m., Monday April 3rd) describes how the VTX-1 platform was adapted and optimized for enriching and characterizing murine and human tumor cells from mouse blood with a high level of capture efficiency. Invasion and clonogenic assays also confirmed the viability and growth rate of cancer cells isolated from mouse blood for future biologic and drug testing studies.

In a third study, Evaluating the metastatic potential and the molecular heterogeneity of patient-derived orthotopic xenograft (PDOX) models of triple-negative breast cancer (poster #1847, to be presented 8 a.m.–12 p.m., Monday April 3rd) researchers at the Stanford University School of Medicine used Vortex’s technology to isolate CTCs from more than 48 different breast cancer derived PDOX models. Different models demonstrated different levels of aggressiveness, represented both by the number of CTCs isolated and the number of micro-mets found in the liver and lung.

In a fourth study, EGFR mutational detection in ctDNA, Vortex-enriched CTCs and comparison to tumor tissue in non-small-cell-lung-cancer (NSCLC) patients (poster #1715, to be presented 8 a.m.–12 p.m., Monday April 3rd), utilizing an off-the-shelf qPCR assay for EGFR mutation profiling was tested for VTX-1 isolated CTCs and cfDNA from the same tube of blood.

“These studies illustrate the potential of Vortex’s microfluidic technology and the automated VTX-1 to empower researchers to take the next step in understanding cancer biology,” explained Chief Scientific Officer Elodie Sollier-Christen.

About Vortex Biosciences
Vortex Biosciences is a cancer research and diagnostics company that integrates cancer biology, microfluidic engineering and informatics to develop tools for isolating and characterizing circulating tumor cells. The Vortex VTX-1 instrument harvests intact circulating tumor cells from whole blood samples for use in downstream research and clinical applications such as patient stratification in clinical trials, monitoring disease progression and drug treatment effectiveness. With a mission to enable noninvasive diagnosis of cancer and real-time monitoring throughout a patient’s treatment, Vortex is at the forefront of accelerating cancer research and improving patient outcomes. Vortex is a core subsidiary of NetScientific plc, a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercializing technologies that significantly improve the health and well-being of people with chronic diseases. For more information, visit http://www.vortexbiosciences.com.

Read the full story at http://www.prweb.com/releases/2017/03/prweb14162646.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Vortex Biosciences Inventor Receives Presidential Award for Research Leading to Groundbreaking "Liquid Biopsy" Technique
2. Vortex Biosciences Appoints Dr. Massimo Cristofanilli As Chairman of Newly Formed Scientific Advisory Board
3. CSO of Vortex Biosciences Dr. Elodie Sollier-Christen Awarded With 2017 SLAS Innovation Award
4. Vortex Biosciences Announces Commercial Launch of Fully Automated System for CTC Isolation
5. New Applications of Pressure BioSciences PCT Platform Prominently Featured at Scientific Conference on Technologies for Protein Research
6. Northstar Biosciences Launches All Natural Skincare Solutions
7. Further Advancements Made in the Development of an Improved Method For Rape Kit Testing Using Pressure BioSciences Patented Pressure Cycling Technology (PCT)
8. Sangamo BioSciences Announces Presentation At Regen Med Investor Day
9. Sangamo BioSciences Announces Presentation At The Needham Healthcare Conference
10. Centrillion Biosciences Announces Next-Gen Sequencing Innovation Grant Program
11. Quanta BioSciences qRT-PCR technology recommended in newly published CDC protocol for detection of H7N9 Avian Influenza
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... NextSteps 2017, NetDimensions’ annual global ... this May on the following dates: , ?    London, UK from May 10-11, ... Learning and Performance Institute will be the opening keynote speaker at the ...
(Date:4/26/2017)... HATFIELD, Pa. , April 26, 2017 /PRNewswire/ ... drug delivery platform, has signed a collaborative and ... through Dr. Silvia Muro . The overall ... pharmacokinetics and pharmacodynamics of various 3DNA designs and ... aims involve targeting diseases of the vasculature as ...
(Date:4/25/2017)... ... April 25, 2017 , ... Franz Inc ... (CL) development tools, and market leader for Semantic Graph Database technology, ... available within the most effective system for developing and deploying applications to solve ...
(Date:4/25/2017)... April 25, 2017 Providence ... licensed its novel immune-modulating technology to an undisclosed global ... allergy. Tregitopes, pronounced T·rej·itopes, are a ... by EpiVax CEO Annie De Groot ... immunoglobulin G, an autoimmune disease therapy, Tregitopes are ...
Breaking Biology Technology:
(Date:3/22/2017)...   Neurotechnology , a provider of high-precision ... the release of the SentiVeillance 6.0 ... recognition using up to 10 surveillance, security and ... new version uses deep neural-network-based facial detection and ... a Graphing Processing Unit (GPU) for enhanced speed. ...
(Date:3/20/2017)... , March 20, 2017 At this year,s ... -based biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG stand ... is this year,s CeBIT partner country. At the largest German biometrics ... in use: fingerprint, face and iris recognition as well as DERMALOG´s multi-biometrics ... ...
(Date:3/13/2017)... of security: Biometric Face Matching software  Continue Reading ... ... match face pictures against each other or against large databases. The recognition of ... ... for biometric Face Matching on the market. The speed is at 100 million ...
Breaking Biology News(10 mins):